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Measurement is the currency of critical care. Illness in the
intensive care unit is defined not by pathologic changes in a
particular tissue or by structural changes in a specific organ,
but by a constellation of quantifiable changes in physiological
and biochemical measures. To round in an intensive care unit
is to be exposed to a cacophony of numbers — the pH, the
Glasgow Coma Scale, the fibrinogen level. To be an
intensivist means to take this chaotic melange of digits and to
transform them into a clinical profile that will support a
therapeutic decision. An uninitiated visitor to a contemporary
intensive care unit could be forgiven for concluding that the
intensivity of intensive care referred to the zeal with which its
practitioners measure things: the continuous recording of the
pulse, the blood pressure and the transcutaneous oxygen
saturation, and the frequent assay of circulating factors whose
function is familiar (e.g. potassium or hemoglobin) as well as
those factors whose biologic significance is less so. High on
the list of those less significant factors is procalcitonin.
In the present issue of Critical Care, Level and colleagues
report the results of a carefully conducted cohort study of
15 patients undergoing continuous venovenous hemodialysis
[1]. They show that procalcitonin (PCT) is cleared by
continuous venovenous hemodialysis at conventional filtration
rates and that the protein adsorbs to the filter, so as much as
20% of PCT is removed through the membrane. The
consequences of this removal are modest, however, and are
probably not clinically significant. Also, the residual plasma
levels remain essentially constant.
What message should the beleaguered intensivist, struggling
to maintain a focus in the face of an onslaught of new
measures and new sources of uncertainty, take from this
report? I believe there are two: one message regarding the
utility of PCT as a diagnostic marker, and the second
message addressing the more fundamental question of how
to interpret the masses of numeric information generated
within the intensive care unit.
PCT is the pro form of the calcium-regulating hormone
calcitonin. A report by Assicot and colleagues a decade ago,
evaluating 79 children suspected of being infected,
suggested that elevated levels of PCT could reliably
discriminate patients who were truly infected from those
patients in whom clinical signs of acute inflammation were
initiated by noninfectious stimuli [2]. Since that report, and
driven in no small part by the development of a reliable assay
for PCT, a Medline search using the keyword ‘procalcitonin’
currently identifies 483 publications. The majority of these
publications addresses the utility of PCT as a diagnostic
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Abstract
Intensivists depend upon a large number of measurements to make daily decisions in the ICU.
However, the reliability of these measures may be jeopardized by the effects of therapy.  Moreover, in
critical illness, what is normal is not necessarily optimal. Procalcitonin, a putative marker of occult
infection, is emerging as a valuable diagnostic marker in the ICU. Although questions remain regarding
its specificity, an increasing body of work suggests that it is reliably elevated in the setting of infection.
As demonstrated by Level and colleagues in this issue of Critical Care, its utility as a diagnostic marker
is not affected by concomitant hemodialysis.
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marker. These studies suggest that, although PCT levels can
be elevated in noninfectious conditions such as the treatment
of transplant rejection with antibodies to CD3 [3], elevated
levels of PCT are a reliable and specific marker of invasive
infection [4–6], and that adequate treatment of such infection
results in a reduction in the levels of circulating PCT [7]. The
utility of PCT as a diagnostic marker appears to be less in its
sensitivity to detect infection than in its specificity to rule it
out [8]. In particular, a low level of PCT permits the clinician
to be confident that infection is not present with greater than
90% certainty.
But if PCT is a promising marker that permits us to conclude
that a critically ill patient is not infected (and so to avoid
noninformative diagnostic investigations or exposure to
unnecessary antibiotics), how confident can we be that the
information it provides can be applied in all critically ill
patients? Clinicians must make categorical, yes/no decisions
based on data that are continuous in character. Arbitrary
cutpoints are therefore established to aid that categorical
decision. A culture of a venous catheter tip is considered
positive if more than 15 colonies of bacteria are present
following a standardized method of culture [9], or transfusion
is administered if the hemoglobin level is less than 70g/l [10].
The validity of each of these thresholds has been established
empirically, but their successful application depends on the
reliability of the measure that is used. Can that reliability be
significantly jeopardized by an artifact resulting from the
confounding effects of the underlying disease or its
treatment? This is the question that Level and colleagues
sought to address, and a question of practical importance to
the interpretation of diagnostic tests in the intensive care unit.
The circulating level of a given molecule depends on three
factors: the rate of production and release of the molecule,
the rate of its removal, and the volume within which it is
diluted. When rates of production and removal are equal, a
steady-state constant level results. However, the actual
measured level of that steady state will depend on the
volume of distribution. Although the kinetics of the synthesis
and release of PCT are not well understood, its synthesis and
release appear to be triggered by invasive infection, with the
result that levels in the circulation increase. The magnitude of
this increase is clearly large enough to offset the reduction in
concentration that might result from the presence of a larger
volume of redistribution in the resuscitated, septic patient. Is
it, therefore, either artefactually increased in renal failure or
reduced by hemodialysis?
Herget-Rosenthal and colleagues studied PCT levels in
68 patients with acute or chronic renal failure treated by
intermittent hemodialysis. They found that elevated PCT
levels had an 84% positive predictive value and an 87%
negative predictive value for the diagnosis of infection. Low
flux membranes did not alter these figures after the start of
dialysis, while high flux membranes did result in a significant
reduction in the negative predictive value to 54% [11]. In
contrast, in a study of 26 patients undergoing continuous
venovenous hemofiltration, Meisner showed that although
PCT was adsorbed to the membrane, and removed in the
ultrafiltrate, plasma levels remained constant [12]. This is a
finding replicated by the present report. It thus appears that
continuous venovenous hemodialysis at conventional flow
rates does not jeopardize the diagnostic utility of PCT;
whether high-volume hemofiltration has an effect remains to
be determined.
From a broader perspective, the evolving literature on PCT
underlines the conceptual quandaries that confront the
contemporary intensivist. Why is the pro form of a calcium-
regulating hormone released during bacterial infection? Is its
release a marker of an appropriate host response to that
infection, or is it a marker of a maladaptive response that
might contribute to the morbidity of sepsis? Is PCT simply a
convenient diagnostic marker, or is it an appropriate target
for therapy [13]? Are the diagnostic criteria of infection used
to evaluate PCT performance indicative of a disease process
(infection) whose timely and appropriate treatment might
improve outcome? Or, rather, are the criteria surrogate
markers of an alternate disease (hyperprocalcitonemia) that
merits therapy in its own right?
The emergence of the intensive care unit as a locus for
providing supportive care for critically ill patients has
confronted us with challenges that are unprecedented in
medical history. Intensive care units care for a population of
patients who, if nature were permitted to take her course,
would die a rapid death. In the absence of fluid replacement
and circulatory support with exogenous catecholamines and
vasoactive agents, the end result of shock is a quiet death
from circulatory insufficiency; without the mechanical
ventilator, hypoxemia similarly leads inevitably to a rapid
demise. But if survival under these circumstances is
unprecedented, how should we interpret the biochemical and
physiologic events that occur in patients who remain alive
only because of the intervention of the intensivist? There is
no compelling evolutionary argument to support the
advantages of one physiologic state over another: those who
in an earlier era would have died do not contribute to the
gene pool, and even in our own brave new age reproduction
while on the ventilator is distinctly uncommon. Under these
circumstances, what is normal may not be what is optimal,
and what is abnormal may not be reliable.
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